The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Influenza
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 36 years and 125 years
- Gender
- Both males and females
Description
Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative. HA contents 15?g/0.5ml per dose includ H1N1?H3N2 and B. Inactivated Split Influenza Vaccine was manufactured by Sanofi Pasteur HA contents 15?g/0.5ml per dose includ H1N1?H3N2 and B. This is a randomized, blind ph...
Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative. HA contents 15?g/0.5ml per dose includ H1N1?H3N2 and B. Inactivated Split Influenza Vaccine was manufactured by Sanofi Pasteur HA contents 15?g/0.5ml per dose includ H1N1?H3N2 and B. This is a randomized, blind phase 3 clinical trial. Total 1200 adults (above ages 36 months ) were selected, randomized to two groups [Influenza Virus Vaccine (Split Virion, Inactivated) and Inactivated Split Influenza Vaccine , each group n=600], adults in each group will be vaccinated with one dose of either Influenza Virus Vaccine (Split Virion, Inactivated) or Sanof IVV respectively.
Tracking Information
- NCT #
- NCT01551810
- Collaborators
- Hebei CDC ,China
- Investigators
- Principal Investigator: Guoyang Liao, Ph. D Chinese Academy of Medical Sciences Principal Investigator: Yuliang Zhao, MD Hubei Provincial Center for Disease Control and Prevention
Get Well Soon